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usculin/MyoR is a new member of basic helix-
loop-helix transcription factors, and its expres-
sion is limited to skeletal muscle precursors.
Here, we report that musculin/MyoR is expressed in adult
kidney side population (SP) cells and can regulate their
function. SP phenotype can be used to purify stem cell–
rich fractions. Microarray analysis clariﬁed that musculin/
MyoR was exclusively expressed in kidney SP cells, and
the cells resided in the renal interstitial space. Musculin/
MyoR-positive cells were decreased in acute renal failure,
but infusion of kidney SP cells increased musculin/MyoR-
M
 
positive cells and improved renal function. Kidney SP
cells in reversible acute renal failure expressed a high
level of renoprotective factors and leukemia inhibitory
factor (LIF), but not in irreversible chronic renal failure. In
cultured kidney SP cells, LIF stimulated gene expression of
renoprotective factors, and down-regulation of musculin/
MyoR augmented LIF-induced gene expression. Our re-
sults suggest that musculin/MyoR may play important
roles not only in developmental processes but also in re-
generative processes in adult tissue.
 
Introduction
 
In 1996, Goodell et al. (1996) reported a new method of obtain-
ing an enriched population of hematopoietic stem cells from
adult mouse bone marrow in a single step by using Hoechst
33342 dye staining and FACS. The isolated cells were called
side population (SP) cells, and the SP phenotype can be used to
purify a stem cell-rich fraction (Zhou et al., 2001; Matsuzaki et
al., 2004). Bone marrow–derived SP cells differentiate into car-
diomyocytes, endothelial cells (Jackson et al., 2001), and os-
teoblast precursors (Olmsted-Davis et al., 2003), and skeletal
muscle SP cells (Asakura et al., 2002) may differentiate into
endothelial cells (Majka et al., 2003). The SP phenotype is de-
termined by BCRP1/ABCG2, and enforced expression of
BCRP1/ABCG2 prevents hematopoietic differentiation (Zhou
et al., 2001). However, the physiological role of this ATP-
binding cassette (ABC) transporter (Gottesman et al., 2002) in
SP cells is still unclear.
In this study, we first tried to clarify the gene expression
profile of kidney SP cells in healthy control and renal failure
models by microarray analysis. The results of microarray and
quantitative PCR analysis clarified that musculin/MyoR is ex-
clusively expressed in kidney SP cells but not in non-SP cells,
and we further examined the functional role of musulin/MyoR
in kidney SP cells. Musculin/MyoR is a newly discovered basic
helix-loop-helix (bHLH) protein that represses myogenesis
(Robb et al., 1998; Lu et al., 1999) and controls facial muscle
development with capsulin (Lu et al., 2002). Musculin/MyoR
mRNA is first expressed at 9.8 days postcoitum in the mouse
embryo, and is almost exclusively restricted to cells of skeletal
muscle lineage, with peak expression at 14–15 days postcoitum.
To our knowledge, no study has confirmed the expression of
musculin/MyoR in adult kidney tissue.
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We then aimed to determine the functional role of
BCRP1 and musculin/MyoR in the kidney. We found that kid-
ney SP cells, but not non-SP cells, are protected from cell
death by BCRP1. Leukemia inhibitory factor (LIF) is up-regu-
lated in reversible cisplatin-induced acute renal failure (ARF),
and is considered to play a role for regeneration process
(Yoshino et al., 2003). In this study, we also examined the ex-
pression of renoprotective factors such as hepatocyte growth
factor (HGF), VEGF, bone morphologic protein (BMP) 7, and
LIF in kidney SP cells. In an ARF model, gene expression of
renoprotective factors and LIF was up-regulated in kidney SP
cells but not in non-SP cells. On the other hand, there was no
up-regulation of renoprotective factors and LIF in irreversible
chronic renal failure (CRF) models. In cultured kidney SP
cells, LIF augmented gene expression of renoprotective fac-
tors. Although inhibition of BCRP1 showed no effect on LIF-
induced gene expression of renoprotective factors, down-regu-
lation of musculin/MyoR augmented it. These results provide
evidence that expression of musculin/MyoR is not limited to
the skeletal muscle lineage and the production of renoprotective
factors in kidney SP cells is regulated by LIF and musculin/
MyoR, but nor by BCRP1.
 
Results
 
Gene expression profile of kidney SP cells
 
We found a significant increase in blood urea nitrogen (BUN)
and IgA in IgA nephropathy (HIGA) mice compared with con-
trol mice (ddY; Table I). In nephrotic syndrome mice (ICGN),
BUN and total cholesterol were significantly increased as com-
pared with control (ICR). We isolated whole kidney cells from
these mice and stained them with Hoechst 33342 dye (Zhou et
al., 2001). The isolated cells were subjected to FACS analysis
in the presence or absence of reserpine to quantitate the number
of cells with a SP and non-SP phenotype (Fig. 1, A and B). As
previously reported (Asakura and Rudnicki, 2002), kidney tis-
sue from control mice (ddY and ICR) contained a much
higher number of reserpine-sensitive SP cells (5.1 
 
  
 
0.1 and
3.1 
 
  
 
0.9%, respectively) than did bone marrow (
 
 
 
1%; not de-
picted). In both renal failure models (HIGA and ICGN), the
population of reserpine-sensitive SP cells in the kidney was re-
duced to 
 
 
 
30% of control (1.5 
 
  
 
0.1 and 1.1 
 
  
 
0.2%, respec-
tively). In our preparation, kidney SP cells were Sca-1 positive
(
 
 
 
70% on average; 
 
n
 
 
 
  
 
20) but CD45 negative (
 
 
 
2% on aver-
age; 
 
n
 
 
 
  
 
20) in all mice, indicating that they were not part of
the hematopoietic system and were not likely to be contami-
nated with peripheral blood SP cells. To characterize kidney SP
cells, gene expression profiling was performed using freshly
isolated kidney SP cells from control (ddY and ICR) and renal
failure models (HIGA and ICGN), as well as cortical tissue of
the kidney from control and renal failure mice. Among the
3,800 genes analyzed, musculin/MyoR (Robb et al., 1998,
1999) was the only gene that was commonly and highly ex-
pressed in SP cells of all mice (greater than sixfold higher com-
pared with cortical tissue; Fig. 1 C, red square with arrow). We
also performed gene expression profiling using kidney SP cells
and non-SP cells, and found that musculin/MyoR was also ex-
pressed greater than sixfold higher in SP cells compared with
non-SP cells in all mice (unpublished data).
 
Immunohistochemical staining of 
musculin/MyoR and BCRP1
 
To confirm the protein expression and localization of musulin/
MyoR-positive cells, we performed immunohistochemical
Figure 1. FACS and microarray analysis of
kidney SP cells. (A) Representative FACS profile
of SP cells isolated from the kidney of normal
(ddY and ICR) and renal failure (HIGA and
ICGN) mice (total events:1.0   10
5 to 3.0  
10
5). (B) Kidney SP cells isolated from ddY,
ICR, HIGA, and ICGN mice stained with
Hoechst dye (white bars). Total event of all
mice were set 1.0   10
5, and uptake of
Hoechst dye was significantly blocked in the
presence of reserpine (res) in all samples
(black bars). Results are presented as the
mean   SEM, n   15. *, P   0.05 versus
control (without reserpine). (C) Scatter-plot
analyses of gene expression (3,800 genes) in
SP cells versus kidney tissue prepared from
normal (ddY and ICR) and renal failure (HIGA
and ICGN) model mice. Average expression
levels of each gene were calculated from three
independent hybridizations.
 
Table I. 
 
Biochemical features in control (ddY and ICR) and CRF 
(HIGA and ICGN) mice
BUN IgA Total cholesterol
 
mg/dl mg/dl mg/dl
 
ddY 20 
 
 
 
 2 98 
 
 
 
 12
 
a
 
ND
HIGA 33 
 
 
 
 3
 
a
 
396 
 
 
 
 26
 
a
 
ND
ICR 36 
 
 
 
 4 ND 108 
 
 
 
 13
ICGN 96 
 
 
 
 4
 
a
 
ND 188 
 
 
 
 12
 
BUN, IgA, and total cholesterol levels in serum. Results are presented as the
mean 
 
 
 
 SEM (
 
n
 
 
 
 
 
 12).
 
a
 
P 
 
 
 
 0.05 versus normal mice. 
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analysis. Kidney SP cells were very small, but strongly ex-
pressed both musculin/MyoR and BCRP1 protein (Fig. 2, A
and B). Although the SP population is a heterogeneous popu-
lation, musculin/MyoR staining clarified that kidney SP cells
were musulin/MyoR positive (
 
 
 
95%), but non-SP cells were
negative (
 
 
 
5%; Fig. S1, available at http://www.jcb.org/cgi/
content/full/jcb.200412167/DC1). In other words, the purity
of kidney SP cells was 
 
 
 
95% with respect to musculin/
MyoR staining. As shown in Fig. 2 (C and D), musculin/
MyoR-positive cells were localized in the interstitial space of
the kidney.
 
BCRP protects SP cells, but not non-SP 
cells, from cell death
 
BCRP1/ABCG2 is a member of ABC transporters, which gen-
erally protect cells from toxic agents (Gottesman et al., 2002).
To clarify the reason why kidney SP cells were decreased in re-
nal failure models (Fig. 1 B) and to examine the protective role
of BCRP1 in kidney SP cells, SP and non-SP cells were treated
with TNF-
 
 
 
. Treatment with TNF-
 
 
 
 (at up to 16 ng/ml) did
not reduce cell viability of non-SP cells, but significantly re-
duced cell viability of SP cells in a concentration-dependent
manner (Fig. 3 A). We further examined the effect of an inhibi-
tor of BCRP1/ABCG2 on TNF-
 
 
 
–induced cell death in kidney
SP cells. Compared with control, reserpine alone showed no ef-
fect (Fig. 3, B and C). TNF-
 
 
 
 alone significantly increased
apoptosis, and cotreatment with TNF-
 
 
 
 and reserpine signifi-
cantly increased it (Fig. 3, B and C).
 
Kidney SP cells contribute to regeneration
 
To clarify the functional role of kidney SP cells in vivo, we in-
jected isolated kidney SP cells systemically via the tail vain
into mice with ARF induced by cisplatin administration
(Ramesh and Reeves, 2002). In this model, i.p. injection of 12
mg/kg cisplatin induced a peaked BUN level on day 7 (Fig. 4 A).
On day 7, musculin/MyoR-positive cells in the interstitial
space were significantly reduced by cisplatin treatment alone,
but kidney SP cell infusion on day 1 significantly increased
these cells on day 7 (Fig. 4, B–E). We also compared the effect
kidney SP cell infusion on renal function to those of infusion of
non-SP cells or bone marrow-derived mononuclear (BM) cells.
Infusion of kidney SP cells significantly suppressed the peak
BUN and creatinine level on day 7 (Fig. 5, A and B), whereas
infusion of non-SP and BM cells had no effect. Tubular necro-
sis scores were also significantly improved by SP cell infusion
(Fig. 5, C and D).
Figure 2. Immunohistochemical analysis of kidney SP cells. (A and B)
Representative photomicrographs of fluorescent images of musculin,
BCRP1, and nuclear staining (TO-PRO3) in cytospin of kidney SP cells
(C57BL/6) just after FACS sorting. Overlay images are shown in the right
panels. (C and D) Representative photomicrographs of fluorescent images
of musculin and nuclear staining in renal tissue (C57BL/6). Musculin-positive
cells (arrows) reside in the interstitial space of the kidney. Overlay images of
musculin and nuclear (yellow) images also showed that the cells reside in
the interstitial space of the kidney.
Figure 3. TNF-   induced cell death in kidney SP cells. (A) Kidney SP and
non-SP cells just after FACS sorting were incubated with TNF-  at the indi-
cated concentrations for 24 h. TNF-  induced cell death in SP cells (black
bars) in a concentration-dependent manner, but not in non-SP cells (white
bars). Cell survival was determined by trypan blue exclusion assay. (B and C)
Kidney SP cells just after FACS sorting were incubated with 50  M reser-
pine (res), 8 ng/ml TNF- , or both for 24 h. Compared with control (no
treatment), TNF-  alone significantly increased DNA fragmentation and
apoptosis, and cotreatment with reserpine significantly augmented it.
DNA fragmentation assay was performed using an ELISA kit, and percent-
age of apoptosis was evaluated by nuclear staining with Hoechst 33258.
Results are presented as means   SEM of four independent experiments.
*, P   0.05 compared with control; **, P   0.05 compared with TNF- . 
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Kidney SP cells express growth factors 
that contribute to tissue regeneration
 
To clarify the role of kidney SP cells in renal failure, we per-
formed quantitative real-time PCR analysis of several factors
that contribute to the kidney regeneration process, such as HGF
(Mizuno et al., 1998), VEGF (Ostendorf et al., 1999), and
BMP7 (Wang and Hirschberg, 2003), in a reversible cisplatin-
induced ARF model and two irreversible CRF models (IgA
nephropathy, HIGA; nephritic syndrome, ICGN). In ARF
mice, kidney SP cells expressed significantly higher levels of
HGF, VEGF, and BMP7 compared with the cells in control
mice (Fig. 6 A). In contrast, in the CRF models, there was no
significant difference between disease mice and control mice
(Fig. 6, B and C). Recently, LIF was reported to be up-regu-
lated and to contribute to regeneration processes (Yoshino et
al., 2003), so we examined the expression of LIF in kidney SP
cells. We also confirmed up-regulation of LIF in the ARF
model but not in the CRF models (Fig. 6 A). On the other hand,
we could not find significant changes of these factors in kidney
non-SP cells of all disease mice as compared with their control
mice (unpublished data).
 
Musculin/MyoR but not BCRP1 
regulates function of kidney SP cells
 
As infusion of kidney SP cells improved renal function in an
ARF model and LIF is also up-regulated in this model, we ex-
amined the effect of LIF on gene expression of renoproptec-
tive factors and musculin/MyoR in kidney SP and non-SP
cells. Compared with control (without LIF), treatment with
LIF significantly up-regulated gene expression of HGF,
VEGF, and BMP7 in SP but not in non-SP cells (Fig. 7, A and
B). To clarify the role of BCRP1 in LIF-induced gene expres-
sion of renoprotective genes, we treated cells with LIF and re-
serpine, but reserpine showed no effect. Retinoic acid (RA) is
reported to down-regulate musculin/MyoR (Yu et al., 2003),
and cotreatment with LIF and RA significantly augmented the
LIF-induced gene expression in kidney SP cells but not in
non-SP cells. Finally, we confirmed the effect of LIF, reser-
pine, and RA on musculin/MyoR expression in SP and non-
SP cells by RT-PCR and real-time PCR. LIF and reserpine
alone showed no effect on basal musculin/MyoR gene expres-
sion, and cotreatment with reserpine also showed no effect
Figure 4. Systemic kidney SP cell infusion increases musculin/MyoR-
positive cells in renal interstitial space in ARF model. (A) Time course of
plasma BUN level in cisplatin-induced ARF model. Values are the mean  
SEM (n   8). *, P   0.05 versus day 0. (B–D) Representative fluorescence
photographs and overlay images (fluorescent and phase contrast) of renal
tissues of control, cisplatin alone (cis), and infusion of kidney SP cells
(cis SP) on day 7. Green spots with red arrowheads are musculin/MyoR-
positive cells. (E) Musculin/MyoR-positive cells were significantly reduced
in the cisplatin-induced ARF model (cis) but were markedly increased by
systemic kidney SP cell infusion (cis SP). Values are the average number
of musculin-positive cells in 10 randomly selected low power fields
( 200) in four independent experiments. Values are the mean   SEM.
*, P   0.05 versus control; **, P   0.05 versus cis.
Figure 5. Systemic kidney SP cell infusion augments recovery
of renal function in ARF model. (A and B) Compared with
control (cont), cisplatin alone (cis) significantly increased the
BUN and creatinine levels, but infusion of kidney SP cells
(cis SP) on day 1 (day after cisplatin injection) significantly
reduced the BUN and creatinine levels on day 7. On the
other hand, infusion of non-SP cells (cis NSP) and BM cells
(cis BM) showed no effect. (C and D) Compared with con-
trol (cont), cisplatin alone (cis) significantly increased the tu-
bular necrosis scores, but infusion of kidney SP cells (cis SP)
on day 1 (day after cisplatin injection) significantly reduced it
on day 7. Values are the mean   SEM. *, P   0.05 versus
control; **, P   0.05 versus cis.MYOR IN KIDNEY SP CELLS • HISHIKAWA ET AL. 925
(Fig. 7, C and D). On the other hand, RA significantly down-
regulated musculin/MyoR in the presence of LIF (Fig. 7, C
and D). In non-SP cells, basal musculin/MyoR expression was
almost absent (Fig. 6 E).
Discussion
Members of the bHLH family of transcription factors are in-
volved in cell fate determination and tissue differentiation in
several developmental processes including hematopoiesis,
myogenesis, and neurogenesis. Musculin/MyoR is a newly dis-
covered bHLH protein that acts as a lineage-restricted repres-
sor of embryonic skeletal muscle development. In this study,
we clarified that musculin/MyoR is expressed in adult kidney
SP cells and regulates LIF-induced gene expression of renopro-
tective factors such as HGF, VEGF, and BMP7.
Robb et al. (1998) failed to detect expression of muscu-
lin/MyoR in adult tissue by Northern blotting but demonstrated
expression in the adult brain, spleen, and muscle but not in the
kidney, liver, lung, or thymus by RNase protection assay. Yu et
al. (2003) detected expression of musculin/MyoR in the adult
brain, heart, liver, lung, small intestine, spleen, and thymus by
Northern blotting. This discrepancy may be explained by the
sensitivity of their assay, but our results also suggest that mus-
culin/MyoR expression is not lineage restricted as has been re-
ported, but is expressed in a relatively broad spectrum of adult
tissue. Musculin/MyoR was originally identified as a transcrip-
tional repressor in embryonic skeletal muscle precursors, but
its function in adult tissue is not known. In fact, musculin/
MyoR knockout mice were not embryonic lethal, and analysis
of kidney function in these mice has not been completed (un-
published data). In the present study, we demonstrated that
down-regulation of musculin/MyoR augmented LIF-induced
gene expression of HGF, VEGF, and BMP7 in kidney SP cells.
These results showed that musculin/MyoR plays a role as a
transcriptional repressor in adult kidney SP cells as reported in
embryonic skeletal muscle. The physiological role of kidney
SP cells is still unclear, but systemic administration of RA,
which down-regulates musculin/MyoR (Yu et al., 2003), aug-
mented the recovery of ARF (Perez et al., 2004). To down-regu-
late musculin/MyoR in vivo, we injected histone deacetylase in-
hibitor trichostatin A (TSA), which down-regulates musculin/
MyoR (Yu et al., 2003), in control and CRF model (nephrotoxic
Figure 6. Quantitative real-time PCR analysis of HGF, VEGF, BMP7, and
LIF in kidney SP cells. (A) Cisplatin-induced gg model. White bars show
control (no treatment) and black bars show cisplatin treatment. Compared
with control, gene expression of HGF, VEGF, BMP7, and LIF was signifi-
cantly up-regulated in kidney SP cells. (B) IgA nephropathy mice. White
bars show control (ddY) and black bars show IgA nephropathy (HIGA).
(C) Nephritic syndrome mice. White bars show control (ICR) and black
bars show nephritic syndrome (ICGN). Expression was normalized to
GAPDH and is shown as the ration to the value of control. Values repre-
sent means   SEM (n   6). *, P   0.05 versus control.
Figure 7. LIF-induced gene expression is regulated by
musculin/MyoR. (A and B) Kidney SP cells (A) or non-SP cells
(B) just after FACS sorting were incubated with vehicle (white
bars), LIF (10 ng/ml; black bars), LIF with reserpine (10 ng/ml
and 50  M, respectively; dotted bars), and LIF with RA (10
ng/ml and 5   10
 7 mol/l, respectively; hatched bars) for
12 h, and then gene expression of HGF, VEGF, and BMP7
was examined by TaqMan real-time PCR. (C and D) Gene
expression of musculin/MyoR in kidney SP cells. An aliquot
of RNA in panel A was examined by RT-PCR (C) and Taq-
Man real-time PCR (D). (E) Gene expression of musculin/
MyoR in non-SP cells. Basal expression of musculin/MyoR
was almost absent. Values represent means   SEM (n   6).
*, P   0.05 versus control; **, P   0.05 versus LIF.JCB • VOLUME 169 • NUMBER 6 • 2005 926
serum model, NTN model). As in the case with HIGA and
ICGN, kidney SP cells analyzed by FACS were reduced in
NTN model. Surprisingly, daily injection (for 21 d) of TSA al-
most completely abolished musculin/MyoR-positive cells in
the kidney of control and NTN model and completely pre-
vented progression of CRF in NTN model. Moreover, regener-
ative factors were also up-regulated by treatment with TSA
(unpublished data). Together, these results suggest that muscu-
lin/MyoR-positive cells could be new targets for regeneration
in renal failure, and we are currently trying to clarify its role us-
ing a renal failure model in musculin/MyoR knockout mice.
Theoretically, an activated transcription factor should be
located within the nucleus, but musculin/MyoR was expressed
throughout kidney SP cells. Inactive sterol regulatory element
binding proteins, another member of the bHLH transcription
factor family, are synthesized as precursors in the cytoplasm
and bind to the endoplasmic reticulum membrane. Upon acti-
vation, the active forms of sterol regulatory element binding
proteins enter the nucleus and activate several genes that con-
trol the synthesis and uptake of cholesterol and unsaturated
fatty acids (Nagoshi and Yoneda, 2001). Pod1, which is also a
bHLH transcription factor expressed in kidney stromal cells
and is required for glomerulogenesis, is distributed throughout
cells located in peritubular interstitial space in the kidney (Cui
et al., 2003). These results suggest that localization of a tran-
scription factor such as musculin/MyoR throughout kidney SP
cells is not unique, but further characterization may be needed
to fully understand its mechanism of translocation.
Infusion of kidney SP cells significantly augmented re-
covery of ARF and increased musculin/MyoR-positive cells in
the interstitial space. Therefore, we speculate that homing of
kidney SP cells to the interstitial space is necessary for regener-
ation in the ARF model induced by cisplatin. Recently, cardiac
stem cells were found in the interstitium between well-differen-
tiated myocytes (Beltrami et al., 2003), and myogenic-endothe-
lial progenitor cells with the SP phenotype were also identified
in the interstitial spaces of skeletal muscle (Tamaki et al., 2002),
suggesting that SP cells commonly reside in the interstitial
space. We also systemically injected kidney SP cells from GFP
mice and DiI-labeled kidney SP cells, and found that these cells
were located in the interstitial spaces of kidney (Fig. S2, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200412167/DC1).
As the interstitial space of the kidney has a fine microcircula-
tion system, musculin/MyoR-positive kidney SP cells in the in-
terstitial space may provide paracrine growth support for neigh-
boring cells in vivo. Several growth factors such as HGF,
VEGF, and BMP7 have been reported to contribute to kidney
regeneration. Especially, BMP7 is the only factor that reverses
chronic renal injury (Zeisberg et al., 2003) and Lin et al. (2005)
recently reported the important role of BMP7 enhancer in CRF.
Administration of exogenous LIF ameliorates glomerulonephri-
tis (Tang et al., 1996), and LIF is up-regulated in ARF (Yoshino
et al., 2003). Therefore, we examined the expression of these
factors in kidney SP cells in renal failure. As shown in Fig. 6
and 7, all of these factors were significantly up-regulated in the
reversible ARF model, but not in the irreversible CRF models,
and LIF increased the gene expression of HGF, VEGF, and
BMP7 in cultured kidney SP cells. Moreover, the number of SP
cells was decreased in the irreversible CRF models (Fig. 1 B).
We also examined the effect of kidney SP cell infusion on CRF
model (unilateral ureteral obstruction model) but found no sig-
nificant improvement (Fig. S3, available at http://www.jcb.org/
cgi/content/full/jcb.200412167/DC1). Recently, we also re-
ported that LIF induces multilineage differentiation of kidney
SP cells in culture (Hishikawa et al., 2005), and some other
pathways can be involved in the restoration of renal function.
Although the precise mechanism regarding the regenerative role
of kidney SP cells remains to be clarified, our results suggest
that loss of musulin/MyoR-positive kidney SP cells and inade-
quate expression of key factors such as LIF and BMP7 in CRF
may determine the fate of CRF.
BCRP1/ABCG2 is reported to determine the SP pheno-
type (Zhou et al., 2001). Enforced expression of BCRP1/
ABCG2 inhibits hematopoietic development (Zhou et al.,
2001), but its mechanism is still unclear. BCRP1/ABCG2 is a
member of ABC transporters (Gottesman et al., 2002) and is
known to transport doxorubicin, daunorubicin, mitoxantrone,
topotecan, and prazocin. Although many ABC transporters
have been identified as drug-resistance proteins, they are all
expressed in normal tissues. Consistent with their wide distri-
bution, it is becoming clear that in addition to exogenously ad-
ministered drugs, ABC proteins transport numerous endoge-
nous substrates. It is well know that ABC transporters have
an important role in protecting the central nervous system
through the blood brain barrier (Schinkel et al., 1996), and
BCRP1/ABCG2 in the placenta may play a role in protect-
ing fetal blood from toxic organic anions and excreting
glutathione/glucuronide metabolites into maternal circulation
(Gottesman et al., 2002). Considering these results, we exam-
ined the protective role of BCRP1 in kidney SP cells. The role
for TNF-  in cisplatin-induced nephrotoxicity has been well
established (Ramesh and Reeves, 2002), and important roles of
TNF-  are also reported in IgA nephropathy (Tuglular et al.,
2003; Chan et al., 2005) and nephrotic syndrome (Suranyi et
al., 1993; Kim et al., 2004; Raveh et al., 2004). As shown in
Fig. 3, kidney SP cells were more sensitive to TNF-  than non-
SP cells, and BCRP1 protected kidney SP cells from cell death.
The precise mechanism of TNF- –induced cell death in kidney
SP cells and direct in vivo evidence linking these effects to pro-
gression of renal failure remain to be determined, but our re-
sults may explain why the number of musculin/MyoR-positive
kidney SP cells was decreased in renal failure in which inflam-
matory cytokines were overexpressed.
In summary, our study provides evidence for a new role
of musculin/MyoR and a protective role of BCRP1 in kidney
SP cells. Our results suggest that members of the bHLH family
of transcription factors such as musculin/MyoR may play im-
portant roles not only in embryonic developmental processes
but also in regenerative processes in adult tissue.
Materials and methods
Mice
HIGA mice (Muso et al., 1996) were donated by E. Muso (Kitano Hospital,
Osaka, Japan). ICGN mice (Ogura et al., 1989) were donated by J.MYOR IN KIDNEY SP CELLS • HISHIKAWA ET AL. 927
Matsuda  (National Institute of Infectious Diseases, Tokyo, Japan). ICR,
ddY, and C57/B6 mice were purchased from Clea Japan. HIGA mice
and their control ddY mice were used for analysis at 14 wk of age. ICGN
mice and their control ICR mice were used for analysis at 30 wk of age. In
Figs. 2, 3, 4, 6 A, and 7, kidney SP and non-SP cells were prepared from
C57B/6 (8 wk old). All the procedures described here were approved by
the Animal Committee of the University of Tokyo.
Clinical biochemistry
Blood samples were measured using an automated analyzer (model Fuji
Dri-Chem 3500V; Fuji Film Co.).
SP cell analysis and cell sorting
Mice were anesthetized and were perfused via the abdominal aorta with
normal saline. Kidneys were harvested and the tissue was minced with a
razor blade and digested by collagenase. The cell suspensions were fil-
tered through a c ell strainer (Falcon 2350; Becton Dickinson) to remove
debris. The filtrates were analyzed as previously described (Matsuzaki et
al., 2004). In brief, after filtration by cell strainer, the kidney cells were
resuspended at 1   10
6 cells/ml in Hank’s balanced salt solution (sup-
plemented with 2% FCS and 10 mM Hepes) and then incubated with 5
 g/ml Hoechst33342 (Sigma-Aldrich) for 60 min for 37 C. A parallel
aliquot was stained with Hoechst33342 in the presence of 50  M of
reserpine (Sigma-Aldrich). As the batch of the Hoechst33342 some-
times affected FACS profile, we screened several batches and ultimately
chose lot number 31K4028 for use in the experiments. Cell analysis and
sorting were performed on a triple laser MoFlo (DakoCytomation).
Hoechst33342 was excited at 350 nm, and fluorescence emission was
detected by using a 405/BP30 and 570/BP20 optical filter for Hoechst
blue and Hoechst red, respectively, and a 550-nm long-pass dichroic mir-
ror to separate the emission wavelengths. Both Hoechst blue and red fluo-
rescence are shown on a linear scale. PI fluorescence was measured
through 630BP30 after excitation at 499 nm with an argon laser, and
live cell gate was defined as that which excluded the cells positive for PI.
After collecting 1   10
5 events, the SP population was defined as reported
previously (Matsuzaki et al., 2004).
Microarray analysis
DNA microarray hybridization experiments were performed using Atlas
glass Mouse3.8 I microarray (CLONTECH Laboratories, Inc.) according to
the manufacturer’s protocol. The protocol and the complete list of genes
can be viewed at the manufacturer’s website. The DNA arrays were
scanned using GenePix4000A (Hishikawa et al., 2001).
Histological analysis
Sections were blocked with 1% skimmed milk (Morinaga) in PBS for 60
min at RT, and then incubated with 2  g/ml of goat anti–mouse musculin
polyclonal antibody (Santa Cruz Biotechnology, Inc.) or rabbit anti-BCRP1
antibody (PC-138; Kamiya Biomedical Company) for overnight at 4 C. Af-
ter washing three times in PBS for 5 min at RT, sections were incubated
with Alexa Fluor 488 or 546 donkey anti–goat IgG (Molecular Probes) or
Alexa Fluor 594 goat anti–rabbit IgG (Molecular Probes) at a dilution of
1:200 for 30 min at RT. All sections were washed three times in PBS for 5
min and then mounted with Pro-Long Antifade kit (Molecular Probes) and
sealed for analysis. For SP cell staining, cells were spun down by cytospin
immediately after FACS sorting. Tissues and cells were also stained with
TO PRO-3 (T-3605; Molecular Probes) for nuclear staining. Stained sec-
tions and cells were observed by a confocal microscope (model TCS SL;
Leica). To adjust laser power, we used sections and cells stained with sec-
ondary antibody alone as negative controls and confirmed that the fluores-
cence is due to reactivity with the primary antibody. Tubular injury was as-
sessed in periodic acid Schiff–stained sections using a semiquantitative
scale in which the percentage of cortical tubules showing epithelial necro-
sis was assessed a score: 0, normal; 1,  10%; 2,10–25%; 3, 26–75%;
4,  75% (Ramesh and Reeves, 2002).
Cell death
The kidney SP and non-SP cells (2   10
3 cells/well were seeded in a 96
multi-well plate) were incubated in DME/F12 with 10% FBS for 24 h just
after FACS sorting. Cell survival was evaluated by trypan blue exclusion
assay, and DNA fragmentation was measured using a cell death detec-
tion ELISA (Roche) according to the manufacturer’s instructions. The per-
centage of apoptosis was evaluated based on nuclear morphology. Cells
were washed with PBS, fixed with fresh 10% PFA for 30 min, and incu-
bated in Hoechst33258 (Sigma-Aldrich) at RT for 30 min (final concentra-
tion, 30  g/ml; Hishikawa et al., 2001).
Cisplatin-induced ARF and SP cell infusion
Mice (C57BL/6; 8 wk old) were given a single i.p. injection of either ve-
hicle (saline) or cisplatin (12 mg/kg of body weight). Several doses of
cisplatin were tested (5–20 mg/kg of body weight), and 12 mg/kg was
chosen to produce mild renal failure with the ability for partial or full recov-
ery. Bone marrow mononuclear cells were isolated from the femurs and tib-
ias of mice by density gradient centrifugation with Ficoll-Paque Plus (Amer-
sham Biosciences). Approximately 10,000 freshly isolated bone marrow
mononuclear, kidney SP, and non-SP cells prepared from C57BL/6 mice
were injected via the tail vein 24 h after cisplatin injection (Table S1, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200412167/DC1).
RT-PCR and real-time PCR
The sequences of primers for RT-PCR were as follows. GAPDH forward 5 -
TGCTGAGTATGTCGTGGA-3  and reverse 5 -AGTTGCTGTTGAAGT-
CGC-3 ; musculin/MyoR forward 5 -GGAGGACCGCTACGAGGACA-
3  and reverse 5 -ACCCACAGAAGGCTATGCT-3 . RT-PCR conditions
for musculin/MyoR and GAPDH were 35 cycles of 94 C for 30 s, 59 C
for 1 min, and 72 C for 1 min. Quantitative real-time PCR was performed
using commercially available TaqMan probes (for HGF, VEGF, BMP7,
and musculin) and analyzed on a sequence detector system (model ABI
PRISM 7000; BD Biosciences). Quantitative values were obtained from
the threshold PCR cycle number at which an increase in signal associ-
ated with exponential growth of the PCR product started to be detected.
The relative mRNA levels in each sample were normalized to its GAPDH
content.
Online supplemental material
Fig. S1 shows immunohistochemical analysis of kidney non-SP cells. Fig. S2
shows engraftment of kidney SP cells in interstitial spaces by systemic kidney
SP cell infusion. Fig. S3 shows the effect of SP cell injection on CRF model
(unilateral ureteral obstruction model). Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200412167/DC1.
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